[Skip to the reading](https://sdpeptides.com/human-results#sd-main)

[SD Peptides](/)

[Why an average leaves questions](/#why-an-average-is-incomplete) · [How we read a reported range](/reading-ranges) · [What the human results can tell us](/human-results)

[SD Peptides](/) / What the human results can tell us

# Even a big trial can’t tell your whole story.

Semaglutide gives us human results to work with. That’s a useful change from trying to guess a human benefit from an animal experiment. An average still isn’t a forecast with your name on it.

We follow three findings here: the average change, how many people reached a goal, and what happened after treatment stopped. Each answers a different question.

## Who was in the average

The [trial enrolled adults with obesity, or overweight and a weight-related condition, without diabetes](https://pubmed.ncbi.nlm.nih.gov/33567185/). Researchers compared a once-weekly semaglutide injection with placebo, a dummy treatment without the active medicine. Both groups also had lifestyle support. These results describe that trial preparation and setting; they don’t establish how a compounded version performs.

![Two adults with different body builds sit comfortably in a sunlit living room.](/sd-spread-cc9456f6a3a9/different-appetites.webp)

The average came from adults, with their own bodies and histories. The people pictured here are illustrations, not members of the semaglutide trial.

Across 68 weeks, [the semaglutide group averaged a loss of roughly 15% of starting weight; placebo averaged around 2%](https://pubmed.ncbi.nlm.nih.gov/33567185/). Those are rounded figures for change from starting weight. They describe these groups in this setting.

That’s a meaningful difference. It doesn’t mean everyone lost that amount. It also can’t tell us what would happen to someone with a different medical history.

## How many reached the goal

In the same trial, [about half the semaglutide group lost at least 15% of their starting weight](https://pubmed.ncbi.nlm.nih.gov/33567185/). Now we’re counting people who crossed a line, rather than averaging everyone’s change.

That adds something useful. The average wasn’t a result everyone shared. We still don’t know each person’s experience from those two summaries, including how far above or below the line they landed.

## What happened after stopping

The follow-up covered a smaller group after both the medicine and lifestyle support stopped. A year later, [regain in the former semaglutide group averaged roughly two-thirds of its earlier loss](https://pubmed.ncbi.nlm.nih.gov/35441470/). This wasn’t the whole original trial group.

That finding matters, but it isn’t an instruction to take a medicine forever. It describes what happened in that follow-up. Treatment length is a personal decision for a patient and prescriber.

## The safety part belongs here too

The [prescribing information lists feeling sick, vomiting, diarrhoea and constipation](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b). Its strongest warning concerns tumours in thyroid C cells, a particular cell type, seen in rodents. We don’t know whether that rodent finding also applies to people.

The label rules out use with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or MEN 2, a rare inherited condition. Serious allergy is another exclusion. If semaglutide itself or any other ingredient has caused a serious allergic reaction before, the label says the medicine is off limits. These details need a clinician’s attention, alongside the rest of someone’s history.

FDA-approved semaglutide medicines exist. A compounded medicine is prepared for a particular patient’s medical needs. [Compounded versions are not FDA-approved](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs). A licensed U.S. clinician can discuss the appropriate options and warnings. We explain the findings without recommending a medicine.

Want to untangle another number? [Read a reported range with us](/reading-ranges).


We explain the room around a result; this is a research guide, not a clinic, pharmacy or seller.

© 2026 SD Peptides

[What the human results can tell us](/human-results)

[The missing steps in healing claims](/repair-claims)

[The distance from a cell to a person](/cell-to-person)

[How we read a reported range](/reading-ranges)

[Follow a sentence back to its source](/references)

[Why we make room around the average](/about)

[What a research question can ask here](/contact)